Skip to main content
Laurus Labs Limited logo

Laurus Labs Limited — Investor Relations & Filings

Ticker · LAURUSLABS ISIN · INE947Q01028 LEI · 335800S8HO8QRYP3VQ26 BSE.NS Manufacturing
Open in API
Filings indexed 705 across all filing types
Latest filing 2024-10-24 Regulatory Filings
Country IN India
Listing BSE.NS LAURUSLABS

About Laurus Labs Limited

https://www.lauruslabs.com/

Laurus Labs Limited is a research-driven organization focused on the development and manufacturing of active pharmaceutical ingredients (APIs), finished dosage forms (FDF), and specialized synthesis services. The company operates across several key therapeutic areas, including anti-retroviral (ARV), oncology, cardiovascular, and anti-diabetic treatments. Through its contract development and manufacturing organization (CDMO) division, it provides integrated drug development solutions to global partners. The company also maintains a biotechnology segment dedicated to recombinant products. Leveraging advanced research and development capabilities alongside large-scale manufacturing infrastructure, the firm emphasizes process chemistry innovation and cost-efficient production to serve diverse global healthcare markets.

Recent filings

Filing Released Lang Actions
Dividend
Regulatory Filings
2024-10-24 English
Financial Result Updates
Regulatory Filings
2024-10-24 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is an invitation to an earnings conference call for Q2 & H1 FY25 results of Laurus Labs. It includes details about the call schedule, dial-in numbers, and a brief company overview. There are no actual financial statements or detailed financial analysis present in the text. The document is clearly an announcement for an upcoming earnings call rather than the earnings release itself or a transcript. Therefore, it fits best under the category of Call Transcript (CT) invitation or announcement. However, since it is only an invite and not the transcript, the closest fitting category is Call Transcript (CT) as it relates directly to the earnings call event. Confidence is high due to explicit mention of earnings call invite and no financial data included.
2024-10-17 English
Board Meeting — LAURUS LABS LIMITED has informed the Exchange about Board Meeting to be held on 24-Oct-2024 to consider and approve the Half Yearly Unaudited Financial results of the Company for the…
Regulatory Filings
2024-10-17 English
Board Meeting — Financial Results/Dividend
Board/Management Information Classification · 95% confidence The document is a formal notification addressed to stock exchanges about an upcoming Board Meeting scheduled for October 24, 2024. It mentions the agenda items including approval of un-audited financial results for the quarter and half year ended September 30, 2024, and consideration of interim dividend payment. The document also informs about the closure of the trading window for insiders. The document is short (1583 characters) and serves as an intimation or announcement rather than containing any financial data or detailed report. It is clearly a Board Meeting Intimation under SEBI regulations, which fits the category of Board/Management Information (MANG). It is not a full financial report, earnings release, or regulatory filing. Therefore, the correct classification is MANG with high confidence.
2024-10-17 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2024. It is addressed to stock exchanges and certifies that details of securities dematerialized/rematerialized have been furnished as required. The document is a formal certification letter from the Registrar and Share Transfer Agent, not a financial report or detailed filing. It is relatively short (3430 characters) and serves as a compliance certificate rather than a report or announcement of voting results, management changes, or financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such regulatory compliance certificates and attestation documents.
2024-10-10 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.